Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 7/20 | 0.66 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.39 |
| ▸ | SELP | P16109 | 2/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042148 | 1.00 | TLR4 (0.66) | TLR4LPAR1MCHR1SELPSSTR3 | |
| SCHEMBL13803789 | 1.00 | TLR4 (0.66) | TLR4LPAR1MCHR1SELPSSTR3 | |
| SCHEMBL10070895 | 1.00 | TLR4 (0.66) | TLR4LPAR1MCHR1SELPSSTR3 | |
| SCHEMBL12762975 | 1.00 | TLR4 (0.66) | TLR4LPAR1MCHR1SELPSSTR3 | |
| SCHEMBL14136616 | 0.96 | TLR4 (0.60) | TLR4MCHR1SSTR3SSTR5SSTR2 | |
| SCHEMBL12836658 | 0.93 | TLR4 (0.58) | TLR4LPAR1SELP | |
| SCHEMBL14136535 | 0.91 | TLR4 (0.70) | TLR4MCHR1SELPSSTR3SSTR5 | |
| SCHEMBL12600779 | 0.85 | TLR4 (0.61) | TLR4LPAR1 | |
| SCHEMBL10042150 | 0.85 | TLR4 (0.61) | TLR4LPAR1 | |
| SCHEMBL13791954 | 0.85 | TLR4 (0.61) | TLR4LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399634-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| US-7906633-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7906633-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | LTB4R2, LTB4R, LITAF | TLR4 24/4885LPAR1 14/4885MCHR1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.